Lantern Pharma (LTRN) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation From FDA For Treatment Of Triple Negative Breast Cancer
BenzingaDec 3 08:12 ET
Express News | Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation From FDA for Treatment of Triple Negative Breast Cancer (Tnbc)
ReutersDec 3 08:00 ET
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
BusinesswireNov 26 08:45 ET
Express News | Lantern Pharma & Starlight Therapeutics Present LP-184 (Star-001) Phase 1B Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (Sno) 2024 Highlighting Novel Synthetic Lethality
ReutersNov 26 08:45 ET
Express News | Lantern Pharma Announces First Patient Dosed in Japan for the Expansion Cohort in the Phase 2 Harmonic™ Clinical Trial of LP-300 in Never-Smoker Nsclc Patients
ReutersNov 19 08:00 ET
Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript
Earnings Call TranscriptsNov 8 19:23 ET

Comments

Jaguar8

Yesterday 06:27

🟢Watchlist Wednesday, December 4. NFA. Check on my previous watchlist. Those without ✅ means they can have delayed market reaction.

Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...

28

7

6

Trytosaveabit

Dec 3 07:06

News

$Lantern Pharma (LTRN.US)$ Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
5 MINUTES AGO, 8:00 AM EST
VIA BUSINESSWIRE

Jaguar8

Dec 3 07:05

NEWS

$Lantern Pharma (LTRN.US)$
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
Tuesday, 3rd December at 8:00 am
• This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024.
• Fast Track Designation for LP-184 recognizes TNBC as a serious condition impacting approximately 29,000 patients annually in th...

Jaguar8

Nov 26 07:48

NEWS

$Lantern Pharma (LTRN.US)$
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
Lantern Pharma and its subsidiary Starlight Therapeutics presented new preclinical data and Phase 1b trial design for LP-184 (STAR-001) in glioblastoma at SNO 2024.
The data shows LP-184 combined with spironolactone increases GBM cell sensitivity up to 6-fold thro...

1

Trytosaveabit

Nov 26 07:48

Update

$Lantern Pharma (LTRN.US)$ Reuters· 2 mins ago
Lantern Pharma & Starlight Therapeutics Present LP-184 (Star-001) Phase 1B Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (Sno) 2024 Highlighting Novel Synthetic Lethality

1

LTRN Lantern Pharma

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target